Walter J Novak

US Patent:

20100152125, Jun 17, 2010

Filed:

Mar 20, 2008

Appl. No.:

12/532309

Inventors:

Jeffrey N. Agar - Newton MA, US
Gregory A. Petsko - Belmont MA, US
Dagmar Ringe - Belmont MA, US
Walter R.P. Novak - Waltham MA, US

Assignee:

Brandeis University - Waltham MA

International Classification:

A61K 31/7034
C12Q 1/02
A61K 31/195
A61K 31/343
A61K 31/55
A61K 31/4015
A61K 31/4709
A61K 31/415
A61K 31/416
A61K 31/4439
A61K 31/15
C07H 21/00
C12N 5/00
C07C 381/00
C07D 307/78
C07D 223/04
C07D 207/18
C07H 15/00
C07D 413/14
C07D 407/02
C07D 231/56
C07D 231/10
C07D 401/02
C07C 243/12
C07D 209/04
A61P 25/28

US Classification:

514 35, 435 29, 514562, 514469, 51421201, 514423, 514314, 514404, 514405, 514338, 514639, 536 221, 435325, 562432, 549468, 540604, 548540, 536 184, 546177, 5483657, 5483601, 5483741, 5462737, 564251, 548483

Abstract:

One aspect of the invention relates to a method of treating or preventing a neurodegenerative disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an inhibitor of the formation of advanced glycation end products. Another aspect of the invention relates to a proteasome activity-based screening assay to select compounds which may be useful for treating or preventing a neurodegenerative disease, and the materials used therein. Yet another aspect of the invention relates to molecules, and methods of use thereof, which bind at or adjacent to SOD-I Trp32, including molecules that bind in a site adjacent to SOD-I Trp32 whether or not it is oxidized, for treating or preventing neurodegenerative disease.